Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced ...

Dermatology Times, Evidence-Based Cleansing and Moisturizing Practices for Protecting and Repairing the Skin Barrier, November 2025 (Vol. 46. Supp. 09) ...

She described the patient consult as the starting point for aesthetic care. It covers the patient’s history, motivation for seeking treatment, prior aesthetic procedures, keloid history, and herpes ...

Trotter said dermatologists should pay attention to locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations ...

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

Personalized prescription skin care is not necessarily designed around a single diagnosis or endpoint. As patients’ skin changes, their treatment goals may shift as well—from ...

For a patient with atopic dermatitis who is ready for systemic therapy, the first priority is getting them on one, Raj Chovatiya, MD, PhD, MSCI, told Dermatology Times in an interview at. “There ...

Ixekizumab is a monoclonal antibody blocking IL-17A from binding its receptor. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which lowers body weight by reducing appetite and calorie intake.

Raj Chovatiya, MD, PhD, MSCI, discusses the FDA approval of remibrutinib for symptomatic dermographism and what an on-label option means for patients. The recent FDA approval of remibrutinib (Rhapsido ...

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results ...